Welcome to our dedicated page for NEWCELX news (Ticker: NLSPW), a resource for investors and traders seeking the latest updates and insights on NEWCELX stock.
The NLSPW news page aggregates announcements and disclosures related to the warrants of NLS Pharmaceutics Ltd., a Swiss-based clinical-stage biopharmaceutical company whose common shares trade on Nasdaq under the symbol NLSP. Because NLSPW is tied to the company’s capital structure, news about these warrants is closely connected to NLS Pharmaceutics’ corporate transactions, financing activities, and strategic developments.
Readers can expect NLSPW-related coverage to reflect key milestones in NLS Pharmaceutics’ evolution, including its proposed and approved merger with Kadimastem Ltd., the planned rebranding and listing of the combined company as NewCelX Ltd. under the ticker NCEL, and the company’s statements that its currently traded warrants will not be listed for trading post-merger. News items often discuss how equity financings, warrant exchanges, and reverse share splits interact with the company’s broader strategic plans.
Beyond capital markets events, NLSPW-linked news will also reference NLS Pharmaceutics’ scientific and clinical updates, since these can influence the context in which the warrants were originally issued. Recent press releases highlight preclinical data for Mazindol in fentanyl use disorder, new findings for the AEX-2 and AEX-41 dual orexin receptor agonists, and expansion of the DOXA platform through collaboration with Aexon Labs. Other announcements describe how the merger with Kadimastem brings together small-molecule CNS programs with cell therapy platforms such as AstroRx® for ALS and IsletRx for diabetes.
By following this page, investors can review how NLSPW fits into the company’s historical financing structure, track corporate actions that may affect the warrants, and read the underlying scientific and strategic news that NLS Pharmaceutics and its merger partner disclose through press releases and SEC-linked communications.
NLS Pharmaceutics (NASDAQ:NLSP) has announced promising preclinical results from in vitro studies targeting alpha-synuclein (A53T mutation) to treat Parkinson's Disease (PD). Utilizing the 'Alpha-Synuclein (A53T) Genetic Cell-Based Agonist Neurite Outgrowth Assay' by Eurofins, various compounds demonstrated positive effects on neurite outgrowth, indicating potential neuronal health benefits.
AEX-23 showed significant OX1R agonist activity and positive neurite outgrowth. AEX-19 showed benefits at low concentrations, increasing CTSD activity and imparting neuroprotective effects. AEX-24 enhanced CTSD activity, suggesting a role in alpha-synuclein degradation.
NLS plans to develop AEX-230 and AEX-231, targeting cathepsins involved in neurodegenerative disorders. Further preclinical and in vivo studies are needed to optimize dosing and assess long-term safety and efficacy.
NLS Pharmaceutics announced that the Nasdaq Hearings Panel has granted the company an extension until October 14, 2024, to meet listing requirements for the Nasdaq Capital Market. The company must comply with a minimum bid price of $1.00 per share and maintain at least $2,500,000 in stockholders' equity, as per Nasdaq Listing Rules 5550(a)(2) and 5550(b)(1). Previously, NLS received notification from Nasdaq that it failed to meet these criteria, prompting a hearing on June 4, 2024. Despite the extension, there are no guarantees that NLS will achieve compliance by the deadlines.
NLS Pharmaceutics, a clinical-stage biopharmaceutical company, has announced a new patent application for dual orexin receptor agonists (DOXA), developed with Aexon Labs, targeting narcolepsy and neurodegenerative diseases like Parkinson's. These non-sulfonamide compounds are designed to reduce side effects and improve patient safety. The molecules enhance neurotransmitter release and protect neuronal health by modulating orexin receptors and inhibiting cathepsin H (CTSH), offering potential therapeutic benefits for sleep regulation and neurodegeneration. This patent represents a significant advancement in addressing unmet medical needs in both narcolepsy and neurodegenerative diseases.
NLS Pharmaceutics announced promising results from study KO-874, presented at the American Society of Clinical Psychopharmacology. The study evaluated mazindol's neuroprotective effects in a narcoleptic-like rat model. Key findings showed that a 3 mg/kg dose of mazindol significantly mitigated circadian activity reduction caused by OX-B-SAP lesions and restored activity levels to normal. Lower doses were less effective. The study highlights mazindol's potential utility in treating disorders like narcolepsy. Further clinical development is supported by these results.
NLS Pharmaceutics (NASDAQ: NLSP) announced it received an additional staff determination letter from Nasdaq on May 22, 2024, notifying the company of its non-compliance with the minimum $2,500,000 stockholders' equity requirement for continued listing. This additional delinquency serves as a separate basis for potential delisting. Previously, on April 19, 2024, NLS was informed of potential delisting due to failing to maintain a $1 bid price per share. The company has requested a hearing before a Nasdaq Hearings Panel, scheduled for June 4, 2024, to appeal the delisting determination and present its plans to regain compliance.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
FAQ
What is the current stock price of NEWCELX (NLSPW)?
